These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 26652966)

  • 21. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S; Deng J; Shi L; Mu Y; Dong H
    J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of clinical pharmacy services on outcomes and costs for indigent patients with diabetes.
    Quinones ME; Pio MY; Chow DH; Moss E; Hulstein JL; Boatright SM; Mathew A
    Am J Manag Care; 2016 Apr; 22(4):e147-52. PubMed ID: 27143351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results?
    Szmurło D; Schubert A; Kostrzewska K; Ryś P; Skrzekowska-Baran I
    Pol Arch Med Wewn; 2011 Oct; 121(10):345-50. PubMed ID: 22045095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients.
    Sicras Mainar A; Roldán Suárez C; Font Ramos B; Navarro Artieda R; Ibáñez Nolla J
    Rev Clin Esp (Barc); 2013 Nov; 213(8):377-84. PubMed ID: 23870706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The SPACE project (Stav Pacientů Akceptovaných diabetologem Cestou Exportu/The Health Records of Patients Accepted by a Diabetologist by way of Export)].
    Kvapil M
    Vnitr Lek; 2016; 62(9 Suppl 3):22-27. PubMed ID: 27734687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Distribution of values of glycated haemoglobin in a population with type 2 diabetes: a project Valetudo].
    Kvapil M
    Vnitr Lek; 2015 Jan; 61(1):81-3. PubMed ID: 25693620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results-Cost-Effectiveness and Budget Impact Analyses.
    Ornstova E; Sebestianova M; Mlcoch T; Lamblova K; Dolezal T
    Value Health Reg Issues; 2018 Sep; 16():92-98. PubMed ID: 30316030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How well we treat with insulin in the Czech Republic and in the Slovak Republic A summary of results and comments on the original Czech-Slovak DIAINFORM study.
    Brož J; Žďárská DJ; Urbanová J; Doničová V; Martinka E; Kvapil M
    Vnitr Lek; 2019; 65(4):279-283. PubMed ID: 31091947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Realistic possibilities of using data sources in quality assessment of care of patients with diabetes in the Czech Republic: National Diabetes Information System].
    Kvapil M
    Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S10-3. PubMed ID: 26652959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of different approaches for estimation of prevalence of type 2 diabetes mellitus in the Czech Republic.
    S PHM; Škodová M; Kučová P; Votápková J
    Vnitr Lek; 2020; 66(5):69-71. PubMed ID: 32942873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in the representation of specialties caring for patients with diabetes in the Czech Republic.
    Kvapil M; Nováková M; Benešová K; Jarkovský J; Dušek L
    Cas Lek Cesk; 2024; 163(3):115-119. PubMed ID: 38981733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.
    Haluzík M; Adamíková A; Běhunčík M; Macko M; Štěpánová R
    Vnitr Lek; 2018; 64(4):357-366. PubMed ID: 29791170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment strategy of type 2 diabetes used in Czech Republic after metformin therapy failure].
    Svačina Š; Ovesná P; Kuhn M; Nováčková M
    Vnitr Lek; 2017; 63(10):647-657. PubMed ID: 29127747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
    Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
    J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical and economic benefits of the new antidiabetic drugs in the Czech Republic].
    Doležal T; Kruntorádová K
    Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S50-3. PubMed ID: 26652966
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.